Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
Adam J. Davenport(Evotec (United Kingdom)), Oliver M. Fischer(Bayer (Germany)), Jens Nagel(Bayer (Germany)), Nikisha Carty(Evotec (Germany)), Thomas M. Zollner(Bayer (Germany)), Frederic Machet, Alexis Laux‐Biehlmann(Bayer (Germany)), Nico Bräuer(Nuvisan (Germany)), Ioana Berindan‐Neagoe(Institute of Oncology Prof. Dr. Ion Chiricuta), Markus Koch(Graz University of Technology), Stephen D. Hess(Evotec (Germany)), Anne-Marie Coelho(Evotec (Germany)), Andrea Rotgeri(Nuvisan (Germany)), Susan Boyce(Evotec (Germany)), Mark J. Gemkow(Evotec (Germany))
Cited by 62
Related Papers
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
|BMC Cancer|2012|561
Psoriasis: a possible risk factor for development of coronary artery calcification
|British Journal of Dermatology|2006|376
Proteasome inhibition: a new anti-inflammatory strategy
|Journal of Molecular Medicine|2003|221
Endothelial P-Selectin as a Target of Heparin Action in Experimental Melanoma Lung Metastasis
|Cancer Research|2004|195
Menstruation pulls the trigger for inflammation and pain in endometriosis
|Trends in Pharmacological Sciences|2015|145